APA Цитирование

Díaz-Rubio, E., Gómez-España, A., Massutí, B., Sastre, J., Abad, A., Valladares, M., . . . Aranda, E. (2012). First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. AlphaMed Press.

Chicago-стиль цитирования

Díaz-Rubio, Eduardo, et al. First-Line XELOX Plus Bevacizumab Followed By XELOX Plus Bevacizumab or Single-Agent Bevacizumab As Maintenance Therapy in Patients With Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. AlphaMed Press, 2012.

MLA-цитирование

Díaz-Rubio, Eduardo, et al. First-Line XELOX Plus Bevacizumab Followed By XELOX Plus Bevacizumab or Single-Agent Bevacizumab As Maintenance Therapy in Patients With Metastatic Colorectal Cancer: The Phase III MACRO TTD Study. AlphaMed Press, 2012.

Предупреждение: эти цитированмия не могут быть всегда правильны на 100%.